Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
16505505

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Blood Glucose /analysis; Diabetes Mellitus, Type 2 /drug therapy; Drug Therapy, Combination; Female; Hemoglobin A, Glycosylated /metabolism; Humans; Hypoglycemic Agents /administration & dosage /therapeutic use; Insulin /administration & dosage /adverse effects /analogs & derivatives /economics /therapeutic use; Insulin Glargine; Insulin, Long-Acting; Lipids /blood; Male; Metformin /administration & dosage /therapeutic use; Middle Aged; Sulfonylurea Compounds /administration & dosage /therapeutic use; Thiazolidinediones /administration & dosage /adverse effects /economics /therapeutic use

AccessionNumber
22006001510

Date bibliographic record published
15/08/2006